'''Nalorphine''' ([[International Nonproprietary Name|INN]]) (brand names '''Lethidrone''', '''Nalline'''), also known as '''''N''-allylnormorphine''', is a mixed [[opioid]] [[agonist–antagonist]] with [[opioid antagonist]] and [[analgesic]] properties.<ref name="Glatt2012">{{cite book|author=M. Glatt|title=The Dependence Phenomenon|url=https://books.google.com/books?id=rN7dBgAAQBAJ&pg=PT121|date=6 December 2012|publisher=Springer Science & Business Media|isbn=978-94-011-7457-2|pages=121–}}</ref> It was introduced in 1954<ref name="Aggrawal">{{cite book|author=Anil Aggrawal|title=APC Essentials of Forensic Medicine and Toxicology|url=https://books.google.com/books?id=iSH8CgAAQBAJ&pg=PA554|publisher=Avichal Publishing Company|isbn=978-81-7739-441-2|pages=554–}}</ref> and was used as an [[antidote]] to reverse [[opioid overdose]] and in a challenge test to determine [[opioid dependence]].<ref>[http://www.time.com/time/magazine/article/0,9171,808859,00.html "Medicine: Drug Detector"], ''[[Time (magazine)|Time]]'', Dec. 24, 1956</ref> It acts at two [[opioid receptor]]s — the [[μ-opioid receptor]] (MOR) where it has [[receptor antagonist|antagonist]]ic effects, and at the [[κ-opioid receptor]] (KOR) (K<sub>i</sub> = 1.6 nM; [[EC50|EC<sub>50</sub>]] = 483 nM; [[intrinsic activity|E<sub>max</sub>]] = 95%) where it exerts high-[[intrinsic activity|efficacy]] [[partial agonist]]/near-[[full agonist]] characteristics.<ref name="GharagozlouHashemi2006">{{cite journal|last1=Gharagozlou|first1=Parham|last2=Hashemi|first2=Ezzat|last3=DeLorey|first3=TimothyM|last4=Clark|first4=J David|last5=Lameh|first5=Jelveh|title=Pharmacological profiles of opioid ligands at Kappa opioid receptors|journal=BMC Pharmacology|volume=6|issue=1|year=2006|pages=3|issn=1471-2210|doi=10.1186/1471-2210-6-3|pmid=16433932|pmc=1403760}}</ref> Nalorphine was the second opioid antagonist to be introduced, preceded by [[nalodeine]] (N-allylnorcodeine) in 1915 and followed by [[naloxone]] in 1960 and [[naltrexone]] in 1963.<ref name="Aggrawal" /> Due to potent activation of the KOR, nalorphine produces [[side effect]]s such as [[dysphoria]], [[anxiety]], [[confusion]], and [[hallucination]]s, and for this reason, is no longer used medically.<ref name="Glatt2012" /><ref name="Aggrawal" /><ref name="SatoskarRege2015">{{cite book|author1=RS Satoskar|author2=Nirmala Rege|author3=SD Bhandarkar|title=Pharmacology and Pharmacotherapeutics|url=https://books.google.com/books?id=h2drCgAAQBAJ&pg=PA166|date=27 July 2015|publisher=Elsevier Health Sciences APAC|isbn=978-81-312-4371-8|pages=166–}}</ref>  Nalorphine has a number of analogues including niconalorphine (the nicomorphine analogue), diacetylnalorphine (heroin analogue) dihydronalorphine(dihydromorphine) and a number of others and a number of codeine-based ones as well.<ref>https://books.google.com/books?id=vwAHCAAAQBAJ&pg=PA507&lpg=PA507&dq=dihydronalorphine&source=bl&ots=_VIpgjuHUF&sig=Xks131s6HpRbIzrp3d1esU5DMsM&hl=en&sa=X&ved=0ahUKEwj6ubPoq-HTAhVJiFQKHb2aA4UQ6AEILDAB </ref>
